Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Tapestry, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Tapestry, Inc. trades at $115.86 (market cap $22.87B). The key difference: Tapestry, Inc. is far larger — about 8× Dyne Therapeutics Inc. Common Stock's market cap, and Tapestry, Inc. pays a 1.61% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Tapestry, Inc. for 70 Days on average.
| DYN | TPR | |
|---|---|---|
Market Cap | $2.86B | $22.87B |
Volume | 3,341,579 | 1,963,570 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $164.78 |
52-Week Low | $14.60 | $98.81 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $2.18B | $25.67B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
TPR trades at $115.03, down 1.87% today, with a neutral technical signal and bearish moving averages. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined to $183M. Recent earnings beats and a $174.64 consensus price target suggest upside potential. International growth in China and Europe supports fiscal 2027 expansion plans.
Outlook remains positive with analyst consensus strongly bullish (73% buy ratings) and 52% upside to price target. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation at 15.85 P/E. Strong cash flow generation and Coach brand momentum provide fundamental support despite recent price weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
